Who are Comirnaty's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): bivalent BNT162b2 (original/Omi BA.4/BA.5), BNT162b2 BA.4/5 bivalent, Combination (Bivalent) BNT162b2 and BNT162b2 OMI, BNT162b2, Low Dose PF-07328948, Famtozinameran 12 Years of age and older.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/comirnaty.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Comirnaty — Competitive Intelligence Brief

Comirnaty (BNT162b2 (tozinameran)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Infectious Disease.

marketed vaccine SARS-CoV-2 virus Infectious Disease mRNA vaccine Live · refreshed every 30 min

Target snapshot

Comirnaty (BNT162b2 (tozinameran)) — Pfizer Inc.. Comirnaty is an mRNA-based vaccine.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comirnaty TARGET	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
bivalent BNT162b2 (original/Omi BA.4/BA.5)	bivalent-bnt162b2-original-omi-ba-4-ba-5	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 virus
BNT162b2 BA.4/5 bivalent	bnt162b2-ba-4-5-bivalent	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 virus
Combination (Bivalent) BNT162b2 and BNT162b2 OMI	combination-bivalent-bnt162b2-and-bnt162b2-omi	Pfizer	marketed	vaccine	SARS-CoV-2 virus
BNT162b2	bnt162b2	Pfizer	marketed	vaccine	SARS-CoV-2 virus
Low Dose PF-07328948	low-dose-pf-07328948	Pfizer	marketed	small molecule	SARS-CoV-2 virus
Famtozinameran 12 Years of age and older	famtozinameran-12-years-of-age-and-older	Pfizer	marketed	monoclonal antibody	SARS-CoV-2 virus

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Comirnaty — Competitive Intelligence Brief. https://druglandscape.com/ci/comirnaty. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab